Y-mAbs Therapeutics (NASDAQ:YMAB) Receives Buy Rating from HC Wainwright

Y-mAbs Therapeutics (NASDAQ:YMAB)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued on Wednesday,Benzinga reports.

A number of other analysts also recently weighed in on the company. Canaccord Genuity Group upgraded Y-mAbs Therapeutics to a “strong-buy” rating in a report on Tuesday, August 13th. Canaccord Genuity Group restated a “buy” rating and set a $26.00 price objective on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. Brookline Capital Management began coverage on Y-mAbs Therapeutics in a report on Thursday, December 5th. They issued a “buy” rating and a $17.00 target price on the stock. Oppenheimer assumed coverage on shares of Y-mAbs Therapeutics in a report on Monday, November 18th. They set an “outperform” rating and a $23.00 price target for the company. Finally, BMO Capital Markets dropped their price target on shares of Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Y-mAbs Therapeutics currently has a consensus rating of “Buy” and an average target price of $20.89.

Y-mAbs Therapeutics Stock Up 0.2 %

Shares of YMAB opened at $10.28 on Wednesday. The business has a 50-day simple moving average of $13.12 and a two-hundred day simple moving average of $12.73. Y-mAbs Therapeutics has a 12-month low of $6.09 and a 12-month high of $20.90. The stock has a market cap of $460.44 million, a PE ratio of -19.04 and a beta of 0.61.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings data on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The business had revenue of $18.46 million during the quarter, compared to the consensus estimate of $23.38 million. During the same quarter last year, the business earned ($0.18) EPS. On average, equities research analysts expect that Y-mAbs Therapeutics will post -0.66 EPS for the current year.

Insider Transactions at Y-mAbs Therapeutics

In other news, insider Thomas Gad sold 30,000 shares of the firm’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $12.97, for a total value of $389,100.00. Following the completion of the sale, the insider now directly owns 67,681 shares in the company, valued at $877,822.57. This trade represents a 30.71 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 22.50% of the company’s stock.

Institutional Trading of Y-mAbs Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD lifted its position in shares of Y-mAbs Therapeutics by 8.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 21,158 shares of the company’s stock valued at $345,000 after purchasing an additional 1,657 shares in the last quarter. Massachusetts Financial Services Co. MA increased its position in shares of Y-mAbs Therapeutics by 3.5% during the second quarter. Massachusetts Financial Services Co. MA now owns 82,202 shares of the company’s stock valued at $993,000 after acquiring an additional 2,760 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Y-mAbs Therapeutics in the third quarter worth $44,000. China Universal Asset Management Co. Ltd. grew its stake in Y-mAbs Therapeutics by 66.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock valued at $113,000 after purchasing an additional 3,416 shares during the period. Finally, Rice Hall James & Associates LLC increased its position in shares of Y-mAbs Therapeutics by 4.2% during the 2nd quarter. Rice Hall James & Associates LLC now owns 89,735 shares of the company’s stock valued at $1,084,000 after purchasing an additional 3,589 shares during the last quarter. 70.85% of the stock is owned by hedge funds and other institutional investors.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.